WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2011143637) IMPROVED COMPLEMENT RECEPTOR 2 (CR2) TARGETING GROUPS
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/2011/143637    International Application No.:    PCT/US2011/036552
Publication Date: 17.11.2011 International Filing Date: 13.05.2011
IPC:
C07K 14/705 (2006.01), C07K 19/00 (2006.01)
Applicants: THE REGENTS OF THE UNIVERSITY OF COLORADO, a Body Corporate [US/US]; 1800 Grant Street, 8th Floor Denver, CO 80203 (US) (For All Designated States Except US).
KOVACS, James [US/US]; (US) (For US Only).
HANNAN, Jonathan P. [GB/GB]; (GB) (For US Only).
HOLERS, V. Michael [US/US]; (US) (For US Only)
Inventors: KOVACS, James; (US).
HANNAN, Jonathan P.; (GB).
HOLERS, V. Michael; (US)
Agent: SHOW, Matthew, D.; Morrison & Foerster LLP 755 Page Mill Road Palo Alto, CA 94304-1018 (US)
Priority Data:
61/345,035 14.05.2010 US
Title (EN) IMPROVED COMPLEMENT RECEPTOR 2 (CR2) TARGETING GROUPS
(FR) GROUPES DE CIBLAGE DES RÉCEPTEURS 2 DU COMPLÉMENT (CR2) AMÉLIORÉS
Abstract: front page image
(EN)Provided herein are compositions and methods directed to soluble proteins which can selectively deliver modulators of complement activity. Targeted delivery of these modulators is accomplished by selectively mutating particular amino acids in a targeting protein portion of the composition corresponding to at least the first two N-terminal SCR domains of CR2. Depending on the particular combination of mutations introduced into the targeting portion, a complement activity modulator can be selectively delivered to particular ligands of CR2 at sites where complement system activation or suppression is desired.
(FR)La présente invention concerne des compositions et des procédés concernant des protéines solubles qui peuvent sélectivement délivrer des modulateurs de l'activité du complément. La délivrance ciblée de ces modulateurs est réalisée par mutation sélective d'acides aminés particuliers dans une partie protéique de ciblage de la composition correspondant au moins aux deux premiers domaines SCR N-terminaux de CR2. Selon la combinaison particulière de mutations introduites dans la partie de ciblage, un modulateur de l'activité du complément peut être sélectivement délivré à des ligands particuliers de CR2 à des sites où l'activation la suppression du système du complément sont souhaitées.
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
African Regional Intellectual Property Organization (BW, GH, GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)